Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001365 · ClinicalTrials.gov registry record · Phase 2
Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
A Phase 2 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00001365 is a Phase 2 study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 42 participants.
The verdict
NCT00001365, a Phase 2 study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
Interventions
- DRUG dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 1993-07 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001365
The ClinicalTrials.gov registry entry for NCT00001365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dextromethorphan is the first listed.
NCT00001365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001365 about?
NCT00001365 is a clinical study titled "Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System". This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missin...
What is the current status of trial NCT00001365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 1993-07. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00001365?
The interventions under investigation include: dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT00001365?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.